Rajiv Khosla, Ph.D.
Chief Executive Officer
Dr. Rajiv Khosla currently serves as Enteris BioPharma’s Chief Executive Officer. He joined the Company in April 2020, bringing more than 30 years of biopharmaceutical industry experience as both a consultant and senior corporate executive to the company. As CEO, Dr. Khosla is leading Enteris as the company targets multiple growth opportunities built around Peptelligence®, the company’s proprietary oral peptide and small molecule drug delivery platform.
During Dr. Khosla’s three-decade career in the biopharmaceutical industry, he has demonstrated an ability to successfully apply his expertise at multiple companies, spanning early-stage to established industry leaders. In 2011, Dr. Khosla founded CEUTEC LLC, a strategy and business development consultancy serving biopharmaceutical companies and venture capital firms. In that capacity, Dr. Khosla consulted with a variety of biopharmaceutical, drug delivery, and medical device companies to implement business strategies, 505(b)(2) product pipeline programs leading to successful FDA filings, and licensing transactions.
Prior to CEUTEC, Dr. Khosla held several senior roles in large and small biopharmaceutical companies, most recently at the former Biovail Corp. as Vice President of Business Development. Dr. Khosla has served on the Boards of Orasi Medical, IntelGenx, and BioNJ. Dr. Khosla received a Bachelor of Pharmacy with honors and a Ph.D. in Pharmaceutical Drug Delivery from the University of Nottingham in England. He earned an Executive M.B.A. from the Henley Business School at the University of Reading. Dr. Khosla is a member of the Royal Pharmaceutical Society of Great Britain.
Paul Shields, Ph.D.
Chief Operating Officer
Dr. Paul Shields is Enteris BioPharma's Chief Operating Officer. He joined the Company in July 2013, initially serving as the Company's Vice President, Operations. He brings more than 24 years of experience in the biopharmaceutical industry, focusing on Chemistry, Manufacturing and Controls (CMC) for a variety of products.
Dr. Shields previously served as the Vice President, Manufacturing Operations for Unigene Laboratories from 2005 to 2013, where he managed commercial CMC operations for recombinant active ingredients, and clinical and commercial supplies of nasal spray and solid dose products. Prior to that, he served as Unigene’s Director of Plant Operations from 2001 through 2005, as Plant Manager from 1995 through 2001, and in various other capacities with Unigene from 1989 through 1995.
Dr. Shields holds a Ph.D. in biochemistry from the University of Pennsylvania and a B.S. in chemical engineering from the University of Michigan.
Gary A. Shangold, M.D.
Chief Medical Officer
Dr. Shangold is Enteris BioPharma’s Chief Medical Officer, joining the Company in January 2020. He brings more than 25 years of pharmaceutical industry and consulting experience in clinical research and regulatory affairs.
Dr. Shangold is a seasoned industry professional having held C-suite level roles at a variety of innovative organizations. Prior to joining Enteris BioPharma, Dr. Shangold was the founder and CEO of InteguRx Therapeutics, a company developing transdermal pharmaceutical products. He was formerly Chief Medical Officer / Executive VP for R&D at Xanodyne Pharmaceuticals. Before that, he was President & CEO of NovaDel Pharma, a publicly-traded specialty pharma company. Earlier still, he worked at Johnson & Johnson Pharmaceutical R&D, where he held several senior roles in Clinical Research and Regulatory Affairs. Prior to J&J, Dr. Shangold was Medical Director of Ob/Gyn/Infertility at Serono Labs.
Before his 25 years in industry, Dr. Shangold spent a decade in academia, on the faculty of The University of Chicago Pritzker School of Medicine, and then later at Massachusetts General Hospital and the Harvard School of Medicine.
Dr. Shangold completed an Ob/Gyn residency at Jackson Memorial Hospital / University of Miami and a fellowship in Reproductive Endocrinology at the L.A. County / University of Southern California Medical Center. He received a BA in Social Behavior from the University of Pennsylvania, and an MD from the Columbia University College of Physicians and Surgeons.